Abingdon Health plc, a leading international lateral flow contract development and manufacturing organization, released a trading update for the fiscal year ended June 30, 2024. The company reported strong commercial progress, with unaudited revenues of £6.1 million, representing a 52% increase compared to the previous year. The second half of the fiscal year showed impressive growth, with a 55% increase in revenue compared to the first half and a 27% increase compared to the same period in the previous year. Abingdon Healths CDMO business contributed significantly to this growth, with a 51% year-on-year revenue increase, as their end-to-end service offering resonated well with customers across various sectors. The acquisition of IVDeology, a regulatory consultancy, strengthened their regulatory service capabilities. Abingdon Products, the companys division focusing on self-test products, also performed well, with a 176% revenue increase in the second half of the fiscal year, driven by the launch of three lateral flow self-tests under the Boots own-label. The company anticipates continued strong revenue growth in FY 2025 and is committed to building a focused, high-quality, sustainable, and profitable business.